Royal Bank Of Canada Nuvation Bio Inc. Transaction History

Royal Bank Of Canada

$422 Billion
Q1 2024

A detailed history of Royal Bank Of Canada transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 20,526 shares of NUVB stock, worth $59,935. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,526

Previous 66,895 69.32%

Holding current value

$59,935

Previous $101,000 26.73%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.46 - $3.97 $67,698 - $184,084	-46,369 Reduced 69.32%	20,526 $74,000
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $40,696 - $64,859	42,392 Added 173.01%	66,895 $101,000
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.1 $11,723 - $19,538	9,304 Added 61.21%	24,503 $32,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $13,551 - $15,984	8,687 Added 133.4%	15,199 $27,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $13,220 - $20,492	-8,263 Reduced 55.93%	6,512 $10,000

Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $22,254 - $33,117	13,247 Added 866.95%	14,775 $28,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $249 - $3,474	860 Added 128.74%	1,528 $3,000
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $29,519 - $53,299	-9,111 Reduced 93.17%	668 $2,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $105,224 - $201,986	-22,875 Reduced 70.05%	9,779 $51,000
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $196,594 - $254,938	25,367 Added 348.11%	32,654 $277,000
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $24,592 - $31,610	3,161 Added 76.61%	7,287 $73,000
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $38,041 - $59,744	4,126 New	4,126 $39,000

Others Institutions Holding NUVB

# of Institutions

126

Shares Held

107M

Call Options Held

40.6K

Put Options Held

2.9K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $634M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Nuvation Bio Inc. Transaction History